Abstract: The present invention relates to a novel endoglycoceramidase whose hydrolytic activity has been substantially reduced or eliminated, such that the enzyme is useful for synthesis of glycolipids from a monosaccharide or oligosaccharide and a ceramide. More specifically, the endoglycoceramidase is a mutant version of a naturally occurring endoglycoceramidase, preferably comprising a mutation within the active site or the nucleophilic site of the enzyme and more preferably comprising a substitution mutation of the Glu residue within the active site or the nucleophilic site. Also disclosed are a method for generating the mutant endoglycoceramidase and a method for enzymatically synthesizing glycolipids using this mutant enzyme.

Abstract: The present invention relates to a novel endoglycoceramidase whose hydrolytic activity has been substantially reduced or eliminated, such that the enzyme is useful for synthesis of glycolipids from a monosaccharide or oligosaccharide and a ceramide. More specifically, the endoglycoceramidase is a mutant version of a naturally occurring endoglycoceramidase, preferably comprising a mutation within the active site or the nucleophilic site of the enzyme and more preferably comprising a substitution mutation of the Glu residue within the active site or the nucleophilic site. Also disclosed are a method for generating the mutant endoglycoceramidase and a method for enzymatically synthesizing glycolipids using this mutant enzyme.

Abstract: The present invention relates to a novel endoglycoceramidase whose hydrolytic activity has been substantially reduced or eliminated, such that the enzyme is useful for synthesis of glycolipids from a monosaccharide or oligosaccharide and a ceramide. More specifically, the endoglycoceramidase is a mutant version of a naturally occurring endoglycoceramidase, preferably comprising a mutation within the active site or the nucleophilic site of the enzyme and more preferably comprising a substitution mutation of the Glu residue within the active site or the nucleophilic site. Also disclosed are a method for generating the mutant endoglycoceramidase and a method for enzymatically synthesizing glycolipids using this mutant enzyme.

Abstract: The present invention relates to a novel endoglycoceramidase whose hydrolytic activity has been substantially reduced or eliminated, such that the enzyme is useful for synthesis of glycolipids from a monosaccharide or oligosaccharide and a ceramide. More specifically, the endoglycoceramidase is a mutant version of a naturally occurring endoglycoceramidase, preferably comprising a mutation within the active site or the nucleophilic site of the enzyme and more preferably comprising a substitution mutation of the Glu residue within the active site or the nucleophilic site. Also disclosed are a method for generating the mutant endoglycoceramidase and a method for enzymatically synthesizing glycolipids using this mutant enzyme.

Abstract: The present invention provides methods of refolding mammalian glycosyltransferases that have been produced in bacterial cells, and methods to use such refolded glycosyltransferases, including glycosyltransferase mutants that have enhanced ability to be refolded. The invention also provides methods of refolding more than one glycosyltransferase in a single vessel, methods to use such refolded glycosyltransferases, and reaction mixtures comprising the refolded glycosyltransferases.

Abstract: The present invention relates to a novel endoglycoceramidase whose hydrolytic activity has been substantially reduced or eliminated, such that the enzyme is useful for synthesis of glycolipids from a monosaccharide or oligosaccharide and a ceramide. More specifically, the endoglycoceramidase is a mutant version of a naturally occurring endoglycoceramidase, preferably comprising a mutation within the active site or the nucleophilic site of the enzyme and more preferably comprising a substitution mutation of the Glu residue within the active site or the nucleophilic site. Also disclosed are a method for generating the mutant endoglycoceramidase and a method for enzymatically synthesizing glycolipids using this mutant enzyme.

Abstract: The present invention provides enhanced methods of producing soluble, active fibroblast growth factor-20 (FGF-20), FGF-21, neurotrophin-3 (NT-3), growth hormone (GH), granulocyte colony stimulating factor (G-CSF), or glucocerebrosidase proteins in microorganisms that have an oxidizing environment.

Abstract: The present invention provides enhanced methods of producing soluble, active fibroblast growth factor-20 (FGF-20), FGF-21, neurotrophin-3 (NT-3), growth hormone (GH), granulocyte colony stimulating factor (G-CSF), or glucocerebrosidase proteins in microorganisms that have an oxidizing environment.

Abstract: The present invention relates to a novel endoglycoceramidase whose hydrolytic activity has been substantially reduced or eliminated, such that the enzyme is useful for synthesis of glycolipids from a monosaccharide or oligosaccharide and a ceramide. More specifically, the endoglycoceramidase is a mutant version of a naturally occurring endoglycoceramidase, preferably comprising a mutation within the active site or the nucleophilic site of the enzyme and more preferably comprising a substitution mutation of the Glu residue within the active site or the nucleophilic site. Also disclosed are a method for generating the mutant endoglycoceramidase and a method for enzymatically synthesizing glycolipids using this mutant enzyme.

Abstract: This invention provides nucleic acid and amino acid sequences of fucosyltransferases from Helicobactor pylori. The invention also provides methods to use the fucosyltransferases to synthesize oligosaccharides, glycoproteins, and glycolipids.

Abstract: The present invention features compositions and methods related to truncated mutants of ST6GalNAcI. In particular, the invention features truncated human, mouse, and chicken ST6GalNAcI polypeptides. The invention also features nucleic acids encoding such truncated polypeptides, as well as vectors, host cells, expression systems, and methods of expressing and using such polypeptides.

Abstract: This invention provides methods for modifying glycosylation patterns of glycopeptides, including recombinantly produced glycopeptides. Also provided are glycopeptide compositions in which the glycopeptides have a homogeneous glycosylation pattern.

Abstract: The present invention relates to methods of providing a protein product to a customer. In particular, the invention relates methods of using protein expression vectors to produce proteins to be provided to a client. The invention also provides vectors for the cloning and expression of proteins, including reagent proteins and therapeutic proteins.

Abstract: This invention provides nucleic acid and amino acid sequences of fucosyltransferases from Helicobactor pylori. The invention also provides methods to use the fucosyltransferases to synthesize oligosaccharides, glycoproteins, and glycolipids.

Abstract: The present invention relates to a method of transferring at least two saccharide units with a polyglycosyltransferase, a polyglycosyltransferase and a gene encoding such a polyglycosyltransferase.

Abstract: The present invention relates to a method of transferring at least two saccharide units with a polyglycosyltransferase, a polyglycosyltransferase and a gene encoding such a polyglycosyltransferase.

Abstract: The present invention relates to a method of transferring at least two saccharide units with a polyglycosyltransferase, a polyglycosyltransferase and a gene encoding such a polyglycosyltransferase.

Abstract: The present invention is directed to compositions for the treatment of respiratory infections caused by a bacteria selected from the group consisting of S. pneumoniae, H. influenzae, H. parainfluenza, Burkholderia (Pseudomonas) cepacia, and a mixture thereof, comprising a binding inhibiting effective amount of the compound of Formula I, ##STR1## where R.sub.1 is H, (.beta.-1)GalNAc-, SO.sub.3 B (where B is H or a cation) or a sialic acid of Formula II; ##STR2## where R.sub.6, R.sub.7, R.sub.8, and R.sub.10 are each independently H, C.sub.1-6 acyl, lactyl, C.sub.1-6 alkyl, sulfate, phosphate, anhydro, a sialic acid of Formula II, (.alpha.-1)Fuc, (.beta.-1)Glc or (.beta.-1)Gal;R.sub.9 is NH--C.sub.1-6 acyl, glycolylamido, amino or hydroxyl; andA is H or a cation;R.sub.2 is H or (.alpha.-1)Fuc-;R.sub.3 and R.sub.4 are each independently OH or NHAc;R.sub.5 is H, SO.sub.

Abstract: The present invention is directed to a method of treating respiratory infections caused by a bacteria selected from the group consisting of S. pneumoniae, H. influenzae, H. parainfluenzae, Burkholderia (Pseudomonas) cepacia and a mixture thereof, by administering a binding inhibiting effective amount of the compound of Formula I, ##STR1## where R.sub.1 is H, (.beta.-1)GalNAc--, SO.sub.3 B (where B is H or a cation) or a sialic acid of Formula II; ##STR2## where R.sub.6, R.sub.7, R.sub.8, and R.sub.10 are each independently H, C.sub.1-6 acyl, lactyl, C.sub.1-6 alkyl, sulfate, phosphate, anhydro, a sialic acid of Formula II, (.alpha.-1)Fuc, (.beta.-1)Glc or (.beta.-1)Gal;R.sub.9 is NH--C.sub.1-6 acyl, glycolylamido, amino or hydroxyl; andA is H or a cation;R.sub.2 is H or (.alpha.-1)Fuc--;R.sub.3 and R.sub.4 are each independently OH or NHAc;R.sub.5 is H, SO.sub.

Abstract: A deodorized polysulfide composition, comprising a major amount of polysulfide material and a minor but effective amount of a deodorizing composition comprising an oil-soluble tertiary alkanolamine of the formula: ##STR1## wherein R.sub.2, R.sub.3 and R.sub.4 are independently alkyl groups of about 1 to 6 carbon atoms; and a monohydric alkyl alcohol containing up to about 12 carbon atoms is disclosed.